Human Medicines: Highlights 2015
January 13, 2016
The European Medicines Agency (EMA) has released an overview of its 2015 key recommendations in relation to the marketing authorisations of new medicines and the safety monitoring of authorised medicines.
In 2015, EMA recommended 93 medicines for marketing authorisation. This includes recommendations for 39 new active substances.
2015 was an important year for public health in the European Union (EU). Therapeutic innovations that have the potential to make a difference to people’s lives were seen in particular for the treatment of certain cancers, cardiovascular diseases, and in the areas of haematology (diseases of the blood) and neurology (disorders of the nervous system).
European Medicines Agency (EMA) maintained its momentum from 2014, granting 93 positive opinions, 39 of which were for new active substances. The agency also recommended 18 orphan drugs for approval, breaking last year's record of 17.
Notably, EMA trailed just behind the US Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) for the year. In 2015, CDER approved 45 new drugs, 21 of which had been granted orphan drug designation by the agency.
While the EU is still slightly behind the US in terms of orphan drug approvals, it has closed the gap significantly in the 16 years since it established incentives for orphan drugs under its orphan regulation, known as Regulation (EC) No 141/2000.
One major difference between the two regulators is the number of drugs that benefited from an expedited review. In 2015, EMA recommended five drugs for approval under its accelerated assessment procedure, which reduces the assessment period for a drug from 210 days to 150. However, in 2015, FDA approved 27 drugs using one or more of the agency's four types of expedited review: fast track, breakthrough, priority review and accelerated approval.
In 2015, EMA recommended three drugs for conditional marketing authorization, Blincyto, Tagrisso and Zykadia. In the EU, a conditional marketing authorization is granted to drugs that fill an unmet need and treat rare or life-threatening diseases using less clinical data than would typically be required, under the condition that the sponsor will complete certain post-authorization study requirements.
EMA also recommended authorization for three drugs, Obizur, Raxone and Strensiq "under exceptional circumstances." This type of authorization allows patients to access drugs for conditions that are too rare to study in a traditional manner, or would be unethical to study. Similar to conditional marketing authorization, drugs authorized under exceptional circumstances generally must follow "specific post-authorization obligations."
Monitoring in real life – optimising safe and effective use
Once a medicine is available to patients, EMA and the national competent authorities of the EU continuously monitor the benefits and risks that patients experience with the medicine in real life.
In 2015, EMA gave new safety advice to manage risks observed with a number of medicines on the market in the EU. The product information of these medicines was updated to provide the best information possible to patients and healthcare professionals to enable informed decisions when using or prescribing a medicine.